REFERENCES
- Tonato M, Mosconi AM, Martin C. Safety profile of Gemci-tabine. Anticancer Drugs 1995; 6(Suppl 6): 27–32.
- Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23(Suppl 10): 32–5.
- Herzig RH, Herzig GP, Wolff SN, Hines JD, Fay JW, Phillips GL. Central nervous system effects of high-dose cytosine arabinoside. Semin Oncol 1987; 14(Suppl 1): 21–4.
- Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1992; 10: 169.
- Lundquist DM, Holmes W. Documentation of neurotoxicity resulting from high-dose cytosine arabinoside. Oncol Nurs Forum 1993; 20: 1409–13.
- Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981; 48: 2577–82.
- Nomura K, Ohno R, Hamaguchi K, Hata T, Hatanaka H, Matsuyama H. Clinicopathological report of cisplatin ence-phalopathy. Rinsho Shinkeigaku 1995; 35: 64–9.
- Higa GM, Wise TC, Crowell EB. Severe disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother 1995; 29: 134–7.
- Brenneke HJ, Weinknecht S, Finck GA, Mitlehner W, Weissbach L. Rare metabolic and cerebral complications after polychemotherapy of a testicular tumor. Urologe A 1994; 33: 484–6.
- Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leucoencephalopathy syn-drome. Am J Neuroradiol 1998; 19: 415–7.
- O'Brien ME, Tonge K, Blake P, Moskovic E, Wiltshaw E. Blindness associated with high-dose carboplatin. Lancet 1992; 339: 558.
- Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999; 5: 501–6.
- Hofstra LS, de Vries EG, Willemse PH. Opthalmic toxicity following paclitaxel infusion. Ann Oncol 1997; 8: 1053.
- Capri G, Munzone E, Tarenzi E, et al. Optic nerve distur-bances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86: 1099–101.